BridgeBio's encaleret shows symptom gains in ADH1 phase 3 trial
Tweet Send to a Friend
BridgeBio Pharma (Nasdaq: BBIO) presented data from its Phase 3 CALIBRATE trial of encaleret in autosomal dominant hypocalcemia type 1 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




